Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neqpiaput Iinruugut (Our Food is Medicine): Testing a Tribally-driven Intervention to Prevent Heart Disease Among Alaska Native Communities

NCT07897838 is registered in ClinicalTrials.gov with University of Alaska Fairbanks as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07897838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Neqpiaput Iinruugut (Our Food is Medicine): Testing a Tribally-driven Intervention to Prevent Heart Disease Among Alaska Native Communities
Lead sponsor
University of Alaska Fairbanks
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
August 31, 2030
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular (cv) risk

Arms

As registered; 1 arm.

  • Neqpiaput Iinruugut (Our Food Is Our Medicine) ExperimentalNeqpiaput linruugut (Our Food is Medicine)

    Participants in all three communities will receive the 12-month Neqpiaput Iinruugut intervention. Communities will be randomly assigned to the order in which they begin the intervention, with intervention start dates staggered by 12 months

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in Framingham Risk Score Baseline (B), 6-month intervention midpoint (T1), 12-month end of intervention (T2), and 18-month follow-up (T3)

    Estimated 10-year risk of coronary heart disease, using the Framingham Risk Score based on age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure medication use, diabetes status, and smoking status. Total and HDL cholesterol are measured from a fasting finger-stick blood sample using a Cholestech LDX point-of-care analyzer, and blood pressure is measured using an OMRON IntelliSense professional digital monitor. Remaining inputs are self-reported on the Demographic and Medical History Questionnaire. Higher scores indicate greater estimated 10-year cardiovascular disease risk.

Papers

PubMed papers this trial cites; 7 papers, results papers first, then newest first.

Source: PubMed, NCBI/NLM (public domain).

Lead sponsor's other trials

University of Alaska Fairbanks, most recent start first.